Correspondence 0001193125-23-134561 from Vanda Pharmaceuticals Inc. (VNDA) (CIK 0001347178) (VNDA)
Vanda Pharmaceuticals Inc. (VNDA) (CIK 0001347178)
Date: May 3, 2023 · CIK: 0001347178 · Accession: 0001193125-23-134561
AI Filing Summary & Sentiment
File numbers found in text: 333-269654
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attn: Cynthia Polynice Re: Vanda Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-269654)
Dear Ms. Polynice:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Vanda Pharmaceuticals Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at 4:30 p.m. Eastern Time on Friday, May 5, 2023 or as soon thereafter as practicable.
The Company hereby acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company hereby authorizes Gregg Griner of Orrick, Herrington & Sutcliffe LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
Please provide a copy of the Commission’s order declaring the Registration Statement effective to Gregg Griner at Orrick, Herrington & Sutcliffe LLP, 222 Berkeley Street, Suite 2000, Boston, MA 02216. If possible, please also send such order by email to the attention of Gregg Griner at ggriner@orrick.com.
Thank you for your attention on this matter.
Very truly yours,
Vanda Pharmaceuticals Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Vanda Pharmaceuticals Inc. 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037 May 3, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Attn: Cynthia Polynice Re: Vanda Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-269654) Dear Ms. Polynice: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Vanda Pharmaceuticals Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at 4:30 p.m. Eastern Time on Friday, May 5, 2023 or as soon thereafter as practicable. The Company hereby acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. The Company hereby authorizes Gregg Griner of Orrick, Herrington & Sutcliffe LLP, counsel to the Company, to orally modify or withdraw this request for acceleration. Please provide a copy of the Commission’s order declaring the Registration Statement effective to Gregg Griner at Orrick, Herrington & Sutcliffe LLP, 222 Berkeley Street, Suite 2000, Boston, MA 02216. If possible, please also send such order by email to the attention of Gregg Griner at ggriner@orrick.com. Thank you for your attention on this matter. Very truly yours, Vanda Pharmaceuticals Inc. By: /s/ Timothy Williams Timothy Williams Senior Vice President, General Counsel and Secretary cc: Gregg Griner, Orrick, Herrington & Sutcliffe LLP Albert Vanderlaan, Orrick, Herrington & Sutcliffe LLP